MIO

MIO analyzes bulk microRNA and gene expression data to identify prognostic and predictive miRNAs, gene interaction network biomarkers, and immune-related signatures for immuno-oncology research.

Key Features:

• Integration of Analysis Methods: Integrates methods to analyze provided and custom bulk microRNA and gene expression data for biomarker discovery and therapeutic target identification.
• Machine Learning Approaches: Applies multiple machine learning techniques to select prognostic and predictive miRNAs and to identify gene interaction network biomarkers.
• Regularized Regression and Survival Analysis: Implements regularized regression models and survival analysis to assess associations between miRNA expression patterns and patient outcomes.
• MicroRNA Target Prediction Tools: Aggregates information from 40 microRNA target prediction tools to support comprehensive target identification and validation.
• Curated Databases: Provides curated immune-related gene and miRNA signatures for analyses focused on immunological aspects of cancer biology.
• TCGA Data Integration: Incorporates processed The Cancer Genome Atlas (TCGA) data, including estimations of infiltrated immune cells and the immunophenoscore.
• Visualization Capabilities: Offers visualization methods to aid interpretation of complex miRNA and gene expression analyses.

Scientific Applications:

• Immuno-oncology research: Investigation of miRNA-mediated regulation of immune responses and the tumor microenvironment.
• Biomarker discovery: Identification of prognostic and predictive miRNAs and gene network biomarkers for patient stratification.
• Therapeutic target identification: Prioritization of miRNA targets and immune-related genes using aggregated target predictions and curated signatures.
• Personalized cancer treatment development: Support for analyses that inform potential personalized treatment strategies based on miRNA and immune-related signatures.

Methodology:

Integration of diverse analysis methods on bulk microRNA and gene expression data; application of multiple machine learning techniques for selection of prognostic and predictive miRNAs and gene interaction network biomarkers; use of regularized regression models and survival analysis; aggregation of results from 40 microRNA target prediction tools; and incorporation of processed TCGA data including estimations of infiltrated immune cells and the immunophenoscore.